Lyell Immunopharma (NASDAQ:LYEL) Stock: Insider Venture Fund Xiii L.P. Arch Purchases 2,321,262 Shares

Key Points

• Major shareholder Venture Fund XIII L.P. Arch purchased 2,321,262 Lyell shares at an average of $10.77 each, investing about $25 million and increasing its holding by 162.72% to 3,747,790 shares.
• Lyell reported promising ronde-cel trial results, with response rates of 91% in the pivotal 3L+ trial and 95% in the 2L cohort; the company also secured about $80 million in private-placement funding to advance the therapy toward a planned BLA, though the stock sale may dilute shareholders.
• Third-quarter results showed a loss of $1.86 per share, narrower than analysts’ $2.06 estimate, but no revenue. Analysts’ average rating was “Moderate Buy,” with an average price target of $40.86.

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) major shareholder Venture Fund Xiii L.P. Arch bought 2,321,262 shares of the firm's stock in a transaction on Wednesday, November 4th. The shares were purchased at an average cost of $10.77 per share, with a total value of $24,999,991.74. Following the transaction, the insider directly owned 3,747,790 shares in the company, valued at approximately $40,363,698.30. This trade represents a 162.72% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL traded down $0.43 during midday trading on Thursday, reaching $15.00. The stock had a trading volume of 657,433 shares, compared to its average volume of 139,964. The firm has a market cap of $367.50 million, a price-to-earnings ratio of -1.17 and a beta of -0.04. Lyell Immunopharma, Inc. has a twelve month low of $7.20 and a twelve month high of $45.00. The company's 50 day moving average price is $10.85 and its 200 day moving average price is $16.73.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.20. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The company had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.01 million. Equities analysts forecast that Lyell Immunopharma, Inc. will post -7.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LYEL has been the subject of a number of research reports. Citigroup reissued a "market outperform" rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. B. Riley Financial assumed coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They issued a "buy" rating and a $44.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a report on Friday, August 14th. Finally, Wall Street Zen raised Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Sunday, October 25th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.86.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. boosted its stake in shares of Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company's stock worth $4,834,000 after buying an additional 264,928 shares during the last quarter. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma during the second quarter valued at approximately $4,744,643. Renaissance Technologies LLC increased its position in shares of Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company's stock valued at $2,335,000 after acquiring an additional 76,921 shares during the last quarter. Velan Capital Investment Management LP lifted its holdings in Lyell Immunopharma by 2.9% during the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company's stock worth $1,475,000 after acquiring an additional 3,000 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Lyell Immunopharma during the first quarter worth $959,000. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma News Summary

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Updated ronde-cel results showed high response rates in patients with relapsed or refractory large B-cell lymphoma: in the pivotal 3L+ trial, the overall response rate was 91% and the complete response rate was 77%; results in the 2L cohort were 95% and 76%, respectively. Severe cytokine release syndrome was not observed in either group. The data will be presented at the ASH meeting and support interest in the therapy’s potential. Article: Positive updated ronde-cel data
• Positive Sentiment: Lyell secured an approximately $80 million private placement to fund ronde-cel development toward a planned biologics license application (BLA). Needham also gave the shares a “Buy” rating, while a Seeking Alpha article cited the clinical progress and financing in an upgrade to “Buy.” Article: $80 million private placement Article: Needham Buy rating Article: Seeking Alpha upgrade
• Neutral Sentiment: Third-quarter loss per share was $1.86, narrower than analysts’ expected $2.06 loss, but revenue was zero. The earnings beat is modestly favorable, though the results underscore Lyell’s pre-commercial stage and ongoing losses. Article: Third-quarter results
• Negative Sentiment: The private placement involves selling common stock, which can dilute existing shareholders. Investors will also be weighing clinical promise against the remaining development and regulatory risks before ronde-cel can reach the market.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell's research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.